Cyclic RGD Conjugated PEG-PLGA Nanoparticle Enhances Preventative Effect of Bilirubin on the Development of Ultraviolet-B (Uvb)-Induced Cataract

Haiying Jin,Yang Huang,Yu Jin,Lijun Wang,Feiyue Xiao,Feng Qian,Chan Zhao
DOI: https://doi.org/10.1016/j.cej.2024.155073
IF: 15.1
2024-01-01
Chemical Engineering Journal
Abstract:Age related cataract (ARC) is characterized by protein conformational disorder with aging stands out as an independent risk factor. Therefore, mitigation of oxidative stress and DNA damage within the lens emerges as a potential therapeutic strategy. While topical administration remains the most common treatment modality for ocular disorder, drug bioavailability is hindered by the cornea epithelium barrier. In this study, we developed a novel cyclic Arg-Gly-Asp (cRGD)-conjugated nanoparticle encapsulating bilirubin (cRNM@BR), an endogenous antioxidant, to combat against cellular senescence and lens opacity associated with ARC. Immunofluorescence staining assay confirmed that cRGD modification significantly prolonged nanoparticle retention on the ocular surface by targeting integrin expressed on corneal epithelium. Moreover, through LC-MS/MS analysis, we demonstrated the enhanced transcorneal penetration efficacy of cRGD-modified nanodrugs both in vivo and in vitro. Our mechanistic investigations revealed that cRNM entered human corneal epithelial cells (HCECs) by clathrin and micropinocytosis-mediated pathways, with the ER/Golgi pathway facilitating its exocytosis. In a mouse model of ultraviolet B (UVB)-induced cataract, topical application of cRNM@BR effectively alleviated intracellular reactive oxygen species (ROS) levels and DNA damage in lens epithelial cells (LECs), thereby preventing cellular senescence and lens opacity. Transcriptomics analysis of LECs in UVB-exposed group and cRNM@BR pretreated group indicated significant enrichment of the cGAS/STING pathway. Further experiments determined that cRNM@BR prevented cellular senescence and lens opacity by ameliorating the cGAS/STING pathway. In conclusion, our findings underscore the therapeutic potential of cRNM@BR in ARC management and highlight the efficacy of cRGD-conjugated nanoplatform for intraocular delivery.
What problem does this paper attempt to address?